Northern Dynasty Minerals Gains Support Against Illegal Veto from Multiple Associations
Northern Dynasty Minerals and its 100%-owned U.S.-based subsidiary Pebble Limited Partnership announce that the National Mining Association, the American Exploration & Mining Association, the Alaska Mining Association and the U.S. Chamber of Commerce have filed Amicus Briefs in the Alaska Federal Court in support of one of the largest undeveloped copper projects in the world, located in the U.S., which is being blocked by an illegal Obama/Biden veto. "We appreciate the important support from the NMA, the AEMA, the AMA and the Chamber, as we fight back against the injustice of the illegal Obama/Biden-era veto," Ron Thiessen, Northern Dynasty President and CEO stated. "The Obama EPA dreamed up this scheme to handicap future mining activity in the U.S., and the Biden EPA put this injustice into action without regard to the economic harm it could cause to all Americans."
Trade with 70% Backtested Accuracy
Analyst Views on NAK
About NAK
About the author
Sarepta Therapeutics Reports Significant Three-Year Study Results
- Clinical Trial Results: Sarepta Therapeutics reported significant three-year results from the EMBARK study, showing that patients treated with Elevidys demonstrated statistically significant efficacy in motor function assessments, leading to a 9.8% stock price increase to $23.20, indicating enhanced competitiveness in Duchenne muscular dystrophy treatment.
- Positive Market Reaction: Following the release of favorable clinical data, there was a surge in demand for Sarepta's shares, reflecting investor optimism about the biopharmaceutical sector's outlook, which may attract more capital into the industry.
- Industry Impact: Sarepta's success could inspire other biopharmaceutical companies to increase investments in rare disease research and development, thereby fostering innovation and growth across the sector.
- Investor Confidence Boost: The success story of Sarepta may bolster investor confidence in biotech stocks, particularly as market conditions continue to favor increased focus on the healthcare sector.
HC Wainwright & Co. Confirms Buy Rating for Northern Dynasty Minerals (NAK)
Analyst Recommendation: HC Wainwright & Co. has reiterated a Buy recommendation for Northern Dynasty Minerals (NYSEAM:NAK) as of December 19, 2025, despite a projected average one-year price target of $0.58/share, indicating a 73.45% downside from its recent closing price of $2.20/share.
Fund Sentiment: There has been a 5.49% increase in the number of funds reporting positions in Northern Dynasty Minerals, with total shares owned by institutions rising by 50.56% to 103,964K shares over the last three months.
Shareholder Activity: Notable changes in shareholder allocations include Kopernik Global Investors increasing its stake by 9.21%, while MIRAE ASSET GLOBAL ETFS HOLDINGS decreased its allocation by 63.51%. COPX - Global X Copper Miners ETF significantly increased its holdings by 508.16%.
Market Outlook: The put/call ratio for NAK is at 0.22, suggesting a bullish outlook among investors, despite the overall negative price target forecast.
